197 related articles for article (PubMed ID: 19763888)
1. PDEF and PDEF-induced proteins as candidate tumor antigens for T cell and antibody-mediated immunotherapy of breast cancer.
Sood AK
Immunol Res; 2010 Mar; 46(1-3):206-15. PubMed ID: 19763888
[TBL] [Abstract][Full Text] [Related]
2. Prostate derived Ets transcription factor and Carcinoembryonic antigen related cell adhesion molecule 6 constitute a highly active oncogenic axis in breast cancer.
Mukhopadhyay A; Khoury T; Stein L; Shrikant P; Sood AK
Oncotarget; 2013 Apr; 4(4):610-21. PubMed ID: 23592399
[TBL] [Abstract][Full Text] [Related]
3. Expression characteristics of prostate-derived Ets factor support a role in breast and prostate cancer progression.
Sood AK; Saxena R; Groth J; Desouki MM; Cheewakriangkrai C; Rodabaugh KJ; Kasyapa CS; Geradts J
Hum Pathol; 2007 Nov; 38(11):1628-38. PubMed ID: 17521701
[TBL] [Abstract][Full Text] [Related]
4. Prostate epithelium-derived Ets transcription factor mRNA is overexpressed in human breast tumors and is a candidate breast tumor marker and a breast tumor antigen.
Ghadersohi A; Sood AK
Clin Cancer Res; 2001 Sep; 7(9):2731-8. PubMed ID: 11555586
[TBL] [Abstract][Full Text] [Related]
5. Prostate-derived Ets transcription factor (PDEF) downregulates survivin expression and inhibits breast cancer cell growth in vitro and xenograft tumor formation in vivo.
Ghadersohi A; Pan D; Fayazi Z; Hicks DG; Winston JS; Li F
Breast Cancer Res Treat; 2007 Mar; 102(1):19-30. PubMed ID: 16897429
[TBL] [Abstract][Full Text] [Related]
6. AR-PDEF pathway promotes tumour proliferation and upregulates MYC-mediated gene transcription by promoting MAD1 degradation in ER-negative breast cancer.
Cao L; Xu C; Xiang G; Liu F; Liu X; Li C; Liu J; Meng Q; Jiao J; Niu Y
Mol Cancer; 2018 Sep; 17(1):136. PubMed ID: 30217192
[TBL] [Abstract][Full Text] [Related]
7. Proteomic analysis of a PDEF Ets transcription factor-interacting protein complex.
Cho JY; Lee M; Ahn JM; Park ES; Cho JH; Lee SJ; Kim BG; Heo SH; Park HJ; Zerbini LF; Hwang D; Libermann TA
J Proteome Res; 2009 Mar; 8(3):1327-37. PubMed ID: 19203193
[TBL] [Abstract][Full Text] [Related]
8. Prostate derived ETS factor (PDEF): a putative tumor metastasis suppressor.
Steffan JJ; Koul HK
Cancer Lett; 2011 Nov; 310(1):109-17. PubMed ID: 21764212
[TBL] [Abstract][Full Text] [Related]
9. Prostate-derived Ets factor, an oncogenic driver in breast cancer.
Sood AK; Geradts J; Young J
Tumour Biol; 2017 May; 39(5):1010428317691688. PubMed ID: 28468594
[TBL] [Abstract][Full Text] [Related]
10. Zebularine Treatment Induces MAGE-A11 Expression and Improves CTL Cytotoxicity Using a Novel Identified HLA-A2-restricted MAGE-A11 Peptide.
Zhang J; Sang M; Gu L; Liu F; Li W; Yin D; Wu Y; Liu S; Huang W; Shan B
J Immunother; 2017; 40(6):211-220. PubMed ID: 28486273
[TBL] [Abstract][Full Text] [Related]
11. Signatures of prostate-derived Ets factor (PDEF) in cancer.
Mahajan N
Tumour Biol; 2016 Nov; 37(11):14335-14340. PubMed ID: 27612480
[TBL] [Abstract][Full Text] [Related]
12. Novel role for PDEF in epithelial cell migration and invasion.
Gunawardane RN; Sgroi DC; Wrobel CN; Koh E; Daley GQ; Brugge JS
Cancer Res; 2005 Dec; 65(24):11572-80. PubMed ID: 16357167
[TBL] [Abstract][Full Text] [Related]
13. Prostate-derived Ets transcription factor overexpression is associated with nodal metastasis and hormone receptor positivity in invasive breast cancer.
Turcotte S; Forget MA; Beauseigle D; Nassif E; Lapointe R
Neoplasia; 2007 Oct; 9(10):788-96. PubMed ID: 17971898
[TBL] [Abstract][Full Text] [Related]
14. PDEF in prostate cancer.
Sood AK; Kim H; Geradts J
Prostate; 2012 May; 72(6):592-6. PubMed ID: 21796651
[TBL] [Abstract][Full Text] [Related]
15. Pdef expression in human breast cancer is correlated with invasive potential and altered gene expression.
Feldman RJ; Sementchenko VI; Gayed M; Fraig MM; Watson DK
Cancer Res; 2003 Aug; 63(15):4626-31. PubMed ID: 12907642
[TBL] [Abstract][Full Text] [Related]
16. Prostate-derived Ets factor is overexpressed in serous epithelial ovarian tumors.
Rodabaugh KJ; Mhawech-Fauceglia P; Groth J; Lele S; Sood AK
Int J Gynecol Pathol; 2007 Jan; 26(1):10-5. PubMed ID: 17197890
[TBL] [Abstract][Full Text] [Related]
17. Clinical significance of PDEF factor expression and its relation to androgen receptor in ER
Cao L; Li C; Xu C; Xiang G; Liu F; Liu X; Jiao J; Lv S; Niu Y
Histopathology; 2018 Nov; 73(5):819-831. PubMed ID: 29969155
[TBL] [Abstract][Full Text] [Related]
18. The immune response to breast cancer, and the case for DC immunotherapy.
Allan CP; Turtle CJ; Mainwaring PN; Pyke C; Hart DN
Cytotherapy; 2004; 6(2):154-63. PubMed ID: 15203992
[TBL] [Abstract][Full Text] [Related]
19. PDEF downregulates stathmin expression in prostate cancer.
Sabherwal Y; Mahajan N; Helseth DL; Gassmann M; Shi H; Zhang M
Int J Oncol; 2012 Jun; 40(6):1889-99. PubMed ID: 22378487
[TBL] [Abstract][Full Text] [Related]
20. A high AR:ERα or PDEF:ERα ratio predicts a sub-optimal response to tamoxifen therapy in ERα-positive breast cancer.
Cao L; Xiang G; Liu F; Xu C; Liu J; Meng Q; Lyu S; Wang S; Niu Y
Cancer Chemother Pharmacol; 2019 Sep; 84(3):609-620. PubMed ID: 31297554
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
